CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Psilocybindrug
Likely dose
Psilocybin 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05305105
NCT05305105Phase 1Completed
CompareCT.gov

Effects of Psilocybin in Post-Treatment Lyme Disease

Johns Hopkins University·interventional·Posted Mar 31, 2022·Updated Aug 20, 2025

In Brief

A Phase 1 clinical trial evaluating Psilocybin for Post-Treatment Lyme Disease and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-Treatment Lyme Disease, Chronic Lyme Disease, Lyme Disease, Chronic
CountriesUnited States
CollaboratorsSteven & Alexandra Cohen Foundation, Usona Institute

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedMar 31, 2022
Enrollment StartJul 1, 2022
Primary CompletionOct 26, 2024
Study CompletionApr 7, 2025
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.3 years ago

Interventions

Psilocybindrug

Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.